Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report

Clinical trial monitoring shows that in the first quarter of 2026, an average of 208 new clinical trial applications were submitted monthly through the Clinical Trials Information System, yielding 668 total submissions of which 538 received authorisation. The median time from submission to decision stood at 118 days, while more than 6,425 initial clinical trials remained ongoing across the EU/EEA, with neoplasms representing the most frequently investigated therapeutic area. Cumulative figures since the system’s launch in January 2022 show 13,778 applications submitted and 11,183 authorisations granted.

Multinational Targets Check

The report tracks two key performance indicators established for the period 2026–2030. The first measures attractiveness through the authorisation of multinational clinical trials, with a target of 25 additional trials per quarter above the pre-Brexit, pre-COVID, pre-C
TIS baseline of 78 per month. Actual authorisations in January, February, and March 2026 totalled 58, 84, and 110 respectively, leaving the cumulative count slightly below the quarterly benchmark of 2,836 trials. The second indicator tracks faster access by measuring the share of trials that begin recruiting at the first EU/EEA site within 200 days of application submission; this proportion remained stable near 40 percent throughout the quarter, with commercial sponsors consistently closer to the target than non-commercial sponsors.

Regulatory Data Backbone

All figures derive exclusively from the Clinical Trials Information System established under Clinical Trials Regulation (EU) No 536/2014, which replaced the earlier Clinical Trials Directive 2001/20/EC following the end of the transition period on 30 January 2025. The data encompass new initial applications, transitioned trials, and resubmissions, and distinguish between mononational and multinational trials as well as commercial and non-commercial sponsors.

Market Access Ripple Effects

Sustained shortfalls in multinational trial authorisations relative to the 2030 target may slow the generation of comparative effectiveness and cost-effectiveness data needed for Health Economics and Outcomes Research (HEOR) submissions, potentially delaying market-access decisions and pricing negotiations in multiple member states simultaneously. The persistent 40 percent recruitment-within-200-days rate, particularly among non-commercial sponsors, highlights operational bottlenecks that extend time-to-revenue for innovative therapies and increase the evidentiary uncertainty faced by payers during reimbursement assessments.